Ascentage Pharma Group International
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | |
| – | +7,505.4% | +47.7% | -79.3% | +616.8% | +3.3% | +122.1% | +48.1% | 0.0% | -7.2% | |
| – | – | – | +156.8% | +4.5% | -36.5% | -52.9% | +42.5% | -33.6% | -0.2% | |
| – | +390.5% | +157.1% | -58.8% | -595.8% | – | – | -108.8% | – | -229.3% | |
| – | +509.2% | +140.8% | +64.6% | +208.9% | +73.6% | -45.7% | -76.0% | -57.3% | +13.5% | |
| – | +44.3% | – | -168.8% | -46.7% | +334.5% | -17.6% | – | -1,751.5% | +176.2% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +3.5% | -77.9% | -100.0% | – | |
| – | – | – | – | – | – | +29.0% | -101.9% | +988.1% | – | |
| – | -87.2% | +1,373.8% | -48.6% | +135.1% | +71.3% | -65.2% | -40.5% | -14.6% | +707.0% | |
| – | -195.0% | – | -123.1% | – | +144.5% | -152.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.